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Malignant mesothelioma (MM) is a fatal cancer of increasing inci-
dence associated with asbestos exposure (Peto et al, 1999). MM
responds poorly to aggressive conventional therapy (Sterman et al,
1999) and has an appalling prognosis. Median survival in the
United Kingdom, where management has been typically palliative,
is between 6 and 12 months from the time of onset of symptoms
(Law et al, 1984; McLean and Patel, 1997; Edwards et al, 2000).
Pathological tumour, nodes and metastasis (TNM) staging is diffi-
cult to achieve. In a large series of patients undergoing extrapleural
pneumonectomy and adjuvant chemoradiotherapy, International
Mesothelioma Interest Group (IMIG) TNM staging (Rusch, 1995)
failed to stratify survival (Sugarbaker et al, 1999), questioning the
value of this approach in predicting outcome. Biological markers
of prognosis have attracted interest in other solid tumours and may
provide prognostic information independent from TNM stage
(Cox et al, 2000a, 2001). 
Angiogenesis is the formation of new blood vessels from
existing vasculature, during which normally quiescent endothelial
cells proliferate and gain invasive characteristics. Angiogenesis is
necessary for tumour growth of greater than 1 to 2 mm in diameter
(Hanahan and Folkman, 1996). High intratumoural microvessel
counts, and indirect measure of the intensity of angiogenesis, are
associated with a poor prognosis in solid tumours (Fox et al, 1995;
Giatromanolaki et al, 1996; Cox et al, 2000b). There have been
preliminary reports of the prognostic value of microvessel counts
in malignant mesothelioma (Kumar-Singh et al, 1997; Ohta et al,
1999). These relatively small studies, of 25 and 54 cases, have
suggested a relationship between increased microvessel counts
and poor prognosis. However methodology, the mean vessel count
obtained and statistical significance varied greatly between the
studies. 
This study incorporated the conclusions of a consensus paper on
the evaluation of tumour angiogenesis into our methodology
(Vermeulen et al, 1996) and evaluated microvessel density (MVD)
in 104 cases of MM. The prognostic significance of MVD was
examined in a multivariate model, incorporating clinical and
pathological factors. The contribution of MVD to the Cancer and
Leukemia Group B (CALGB) (Herndon et al, 1998) and European
Organisation for the Research and Treatment of Cancer (EORTC)
(Curran et al, 1998) prognostic scoring systems, which we have
validated previously in this cohort of patients (Edwards et al,
2000), was analysed. 
MATERIALS AND METHODS 
Patients 
All cases of MM presenting to our institution since 1988 were
identified and case notes reviewed. Relevant demographic, clinical
and pathological data were retrieved. Clinicopathological prog-
nostic factors, including CALGB (Herndon et al, 1998) and
EORTC (Curran et al, 1998) prognostic groups were assessed, 
as described previously (Edwards et al, 2000). The majority 
of patients were referred to the regional Department of
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BJOC 01-1997 863-868  10/9/01  1:56 pm  Page 863Cardiothoracic Surgery for surgical biopsy, management of pleural
effusion or empyema, or for radical surgery. The detailed histo-
pathological report was obtained for each case and the slides
reviewed by a pathologist to both confirm the diagnosis and to
assess the most suitable block for microvessel quantification. One
block was selected and a single histological section stained, as this
has been shown to be representative of tumour angiogenesis as a
whole in breast cancer (Martin et al, 1997b). Cancer-specific
survival was calculated from the date of the diagnostic biopsy. 
Pre-diagnostic variables, such as performance status and haemato-
logical indices, were taken from immediately before this time. 
Immunohistochemistry 
Representative formalin-fixed paraffin-embedded blocks of tumour
were chosen for each case. 4 µ m sections were cut onto glass
slides previously treated with 2% 3-aminopropylethoxysilane.
Sections were dewaxed in xylene and rehydrated through graded
alcohols. Endogenous peroxidase activity was blocked by immer-
sion in 2% hydrogen peroxide for 30 minutes. Sections were
rinsed in deionised water followed by tris-buffered saline (TBS)
containing 0.1% bovine serum albumin. Non-specific staining was
blocked by incubation with 20% normal rabbit serum for 10
minutes. Sections were incubated overnight at 4˚C with CD34
antibody (NCL-END, Novocastra, Newcastle, UK) at a dilution of
1 in 50. Following washing in TBS, sections were incubated for 30
minutes with a biotinylated rabbit anti-mouse whole immunoglob-
ulin secondary antibody (E0354, Dako, Ely, UK). Sections were
rinsed in TBS before incubation with streptavidin–biotin peroxi-
dase complex (K0377, Dako) for 30 minutes. Finally, sections
were rinsed in TBS and incubated with the chromogen
diaminobenzidine tetrahydrochloride for 10 minutes before coun-
terstaining with haematoxylin. Sections were dehydrated through
graded alcohols and mounted in resinous mountant. Negative
controls had the primary antibody omitted, whilst microvessels
from surrounding normal lung were used as an internal positive
control. 
Microvessel quantification 
Angiogenesis was assessed indirectly with the aid of a Chalkley
eyepiece graticule, as previously described (Cox et al, 2000b).
Each section was examined under low power to identify 3 intratu-
moural microvessel ‘hot spots’. These areas were then examined at
×  250 magnification using a 25-point Chalkley eyepiece graticule.
The Chalkley graticule was orientated so that the maximum
number of points coincided with immunostained structures.
Structures with the morphological features of microvessels that
stained with the chromogen, irrespective of whether a lumen was
present, were counted. MVD was defined in this study as the sum
of the number of points thus counted from 3 hot spots. The
Chalkley graticule covers an area of 0.115 mm2 at ×  250 magnifi-
cation. Sections were analysed by 2 investigators blinded to
clinicopathological factors and outcome. 
Statistical analysis 
Statistical analysis was performed using the SPSS software system
(SPSS for Windows Version 9.0, SPSS Inc, Chicago, USA).
Differences in total Chalkley count within categorical prognostic
factors were assessed with Student’s  t-test. Linear regression
analysis was used to assess correlations with continuous prog-
nostic variables. Cancer-specific survival curves were estimated
using the Kaplan–Meier method and the log-rank test was used to
assess the statistical significance of differences between groups. A
Cox proportional hazards regression model was used to identify
statistically significant differences in survival and estimate hazard
ratios and 95% confidence intervals (CI) (Cox, 1972). The
assumption of proportional hazards was assessed graphically by
plotting log[-log(survivor)] against log(time) for each of the
prognostic groups. Prognostic variables identified by univariate
analysis, with P < 0.1, were analysed in a multivariate Cox model.
Cases in which complete prognostic data retrieval was not possible
(due to missing or destroyed case notes, or missing data within
case notes that had been inspected) were excluded from multi-
variate analysis. A forward, stepwise selection procedure was
used, with variables being added to the model according to a
partial likelihood ratio test, using an entry criterion of P < 0.05. 
RESULTS 
Patient characteristics and immunohistochemistry
results 
In all cases, microvessels stained for CD34 but tumour cells did
not. Figures 1 and 2 show examples of anti-CD34 immunostaining
with a high and low MVD. Of the 140 cases of MM presenting to
our department, 36 had insufficient material for microvessel
counting (i.e. less than 3 full high power fields of tumour). In the
remaining 104 cases, immunostaining of stromal elements, which
had the morphological features of myofibroblasts, was present in
18 (17%) cases (Figure 3). Microvessel quantification was only
carried out in 7 of these cases in which the morphological pattern
of stromal staining was clearly distinct from that of microvessels.
Stromal staining therefore precluded microvessel quantification
in 11 (11%) cases. In the 93 cases successfully assessed with
microvessel counting the surgical procedures performed were
biopsy alone (54 cases), parietal pleurectomy (18), decortication
(33) and extrapleural pneumonectomy (8). Immunohistochemistry
was required in 52% of these cases to confirm the diagnosis. The
most commonly used markers were CEA, BerEP4, AUA-1, cyto-
keratin, thrombomodulin, HBME-1 and CAM 5.2 in 41, 38, 27,
22, 19 and 16 cases respectively. Of the 93 cases in which MVD
was derived, cell type was epithelioid in 48, mixed cellularity in
18 and sarcomatoid in 27. It did not prove possible to derive an
accurate IMIG TNM stage from this cohort of patients: 58% of
patients underwent computed tomography, but pathological verifi-
cation of stage was only available in 20 (21.5%) patients. 
Microvessel quantification 
The median Chalkley count (sum of 3 hotspots) in the 93 cases
was 23 (range 13–29). There was no significant difference in
Chalkley count between epithelial and non-epithelial cell types,
nor within other categorical prognostic factors (data not shown).
However, a trend towards a positive correlation between cases
with vessel counts ≥ median and weight loss of greater than 5% 
(P = 0.055) was noted. With linear regression analysis, a signifi-
cant correlation was seen between increasing MVD and platelet
count (P = 0.048, Table 1), but not with white cell count, haemo-
globin or age. Furthermore a positive correlation was seen between
high platelet counts and weight loss > 5% (P < 0.0001). There was
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groups of the EORTC prognostic scoring system. With regard to
the CALGB system, even numbered groups displayed small
numbers and so groups were combined for statistical analysis.
Although a significant difference in MVD was noted between
Groups 3 and 4 compared to Groups 5 and 6, there was no signifi-
cant overall trend towards increased MVD in the higher risk
groups. 
Survival 
Overall median survival from the date of histological diagnosis for
the 93 cases was 5.0 months. 12 cases died within 30 days.
Excluding these cases did not have a significant effect on any of
the survival analyses: therefore all 93 cases were included. When
entered into a Cox proportional hazards model, high MVD was a
poor prognostic factor as a continuous variable (P = 0.02) and as a
categorical variable at cut points from the 20th centile up to the
median (P = 0.007) (Figure 4). Other statistically significant poor
prognostic factors by univariate Cox proportional hazards analysis
were increasing age (P = 0.03), weight loss > 5% (P = 0.002),
presence of pleuritic chest pain (P = 0.03), Eastern Co-operative
Oncology Group (ECOG) performance status > 0 (P < 0.0001),
white blood count (WBC) > 8.3 × 109 l–1 (P = 0.02) and cell type
(P = 0.0001, Table 2). 10 cases were excluded from multivariate
analysis due to missing prognostic data in case notes. In multi-
variate analysis, non-epithelial cell type was the strongest indepen-
dent risk factor followed by performance status > 0 and increasing
MVD (Table 3). When tested against the prognostic scoring
systems in Cox multivariate analysis, increasing MVD contributed
independently to the EORTC system (P = 0.006) but not the
CALGB system (P = 0.1, Table 4). 
DISCUSSION 
This study demonstrates that increased MVD, as assessed by
Chalkley counting, is an independent prognostic factor in MM.
This is in agreement with other solid tumours and with 2 previous
reports in MM (Kumar-Singh et al, 1997; Ohta et al, 1999). Kumar
Singh et al found that MVD was a significant prognostic factor in
univariate analysis and was independent of MM cell type, tumour
grade and patient age in multivariate analysis (Kumar-Singh et al,
1997). However, total microvessel area, when calculated from
computer-aided image analysis, was not a significant prognostic
factor, thus suggesting that the size of microvessels is not as
important as their number. Ohta et al examined both MVD and
lymphatic vessel density in 54 tumours and found statistically
insignificant trends between high MVD and both poor survival and
positive lymph node status. In multivariate analysis, gender, IMIG
stage and high MVD were significant independent poor prognostic
factors. In a further study, Tolnay et al noted that MVD correlated
with expression of the angiogenic growth factor hepatocyte growth
factor/scatter factor (HGF/SF) but did not comment on any rela-
tionship to prognosis (Tolnay et al, 1998). 
The protocol for this study was based on the findings of an inter-
national consenus paper on the quantification of angiogenesis in
solid tumours (Vermeulen et al, 1996). This suggested that manual
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Figure 1 Photomicrograph of a tumour section with a high microvessel
density (× 200, bar = 50 µ m) 
Figure 2 Photomicrograph of a tumour section with a low microvessel
density (× 200, bar = 50 µ m) 
Figure 3 Photomicrograph of a tumour section displaying stromal anti-
CD34 immunostaining, which prevented accurate assessment of microvessel
density (× 250, bar = 50 µ m)  
Table 1 Correlation of clinicopathological prognostic factors with MVD by
linear regression analysis 
rP
WBC 0.06 0.57 
Platelets 0.21 0.048 
Haemoglobin 0.04 0.71 
Age 0.06 0.53 
BJOC 01-1997 863-868  10/9/01  1:56 pm  Page 865vessel counting in hot spots was the appropriate method for
assessing angiogenesis objectively in tumours and that either anti-
CD34 or CD31 antibodies should be used. The anti-CD34 mono-
clonal antibody was chosen for this study as it has been shown 
to give more reproducible immunostaining of microvessels than
either the anti-CD31 or anti-Factor VIII monoclonal antibodies in
breast cancer (Martin et al, 1997a). This choice was supported by
Kumar-Singh et al who found that CD34 staining was better
delineated and easier to assess than CD31 in MM (Kumar-Singh
et al, 1997). Stromal staining was seen in 18 cases in our
series. In 7 cases the pattern of stromal staining was clearly
morphologically distinct from that seen in microvessels and these 
were included in the analysis. Kumar-Singh described a 
‘perivascular wash’ in some cases with anti-CD34 immuno-
histochemistry, but did not report staining of specific stromal
elements. In no case was MM tumour-cell CD 34 positivity seen,
in keeping with a recent report (Attanoos et al, 2000). The
Chalkley counting method of MVD assessment was chosen
because it has been shown to be a rapid and objective method of
MVD assessment in breast (Fox et al, 1995; Hansen et al, 2000),
bladder (Dickinson et al, 1994; Chaudhary et al, 1999) and non-
small-cell lung cancers (Giatromanolaki et al, 1996; Cox et al,
2000b). 
A significant correlation with the platelet count was seen in this
study. This supports the hypothesis that platelets may play an
important role in tumour angiogenesis. Platelets are an important
source of angiogenic growth factors such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF)
(Banks et al, 1998; Pinedo et al, 1998). Platelets are likely to
adhere to intratumoural endothelium, which can lead to platelet
activation and the release and accumulation of high local concen-
trations of these growth factors (Pinedo et al, 1998; Verheul et al,
2000). A positive correlation has been established between serum
VEGF and platelet count in cancer patients (Vermeulen et al,
866 JG Edwards et al 
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Table 2 Prognostic factors analysed in a univariate Cox proportional hazards model, for cases with satisfactory MVD assessment (n = 93) 
Variable n Hazard ratio Hazard ratio 95% confidence intervals P
Gender Female 8 
Male 85 2.19 0.95 5.07 0.07 
Age 93 1.03 1.00 1.05 0.03 
Weight loss No 38 
Yes 47 2.02 1.28 3.19 0.002 
Asbestos exposure No 14 
Yes 61 0.70 0.38 1.26 0.2 
Chest pain No 22 
Yes 66 1.79 1.07 3.00 0.03 
ECOG performance status 0 37 
1 or 2 52 2.61 1.66 4.11 < 0.001 
WBC < 8.3 × 109 l–1 25 
> 8.3 × 109 l–1 61 1.77 1.08 2.90 0.02 
Platelets < 400 × 109 l–1 51 
> 400 × 109 l–1 35 1.48 0.95 2.31 0.09 
Haemoglobin > 14 g dl–1 56 
< 14 g dl–1 31 1.39 0.87 2.22 0.2 
Cell Type Epithelial 47 
Mixed or sarcomatoid 46 2.46 1.57  3.85 0.0001 
Surgical resection Yes 55 
No 38 1.33 0.82 2.16 0.2 
EORTC Low risk 31 
High risk 56 2.33 1.45 3.74  0.0005 
CALGB Groups 1 and 2 14 
Groups 3 and 4 41 2.39 1.14 5.00 0.02 
Groups 5 and 6 31 6.51 2.94 14.39 < 0.0001 
Microvessel density 93 1.03 1.01 1.05 0.02 
Table 3 Significant prognostic variables identified in a forward, stepwise,
multivariate Cox proportional hazards model (MVD was analysed as a
continuous variable) 
Factor Hazard ratio 95% Confidence interval  P
Non-epithelial cell type 2.23 1.35–3.67 0.002 
Performance status > 0 2.10 1.29–3.43 0.003 
MVD 1.04 1.01–1.06 0.01 
Table 4 Contribution of MVD to CALGB and EORTC prognostic scoring
systems in multivariate Cox proportional hazards analysis 
Factor Hazard ratio 95% Confidence interval  P
CALGB Groups 1/2 1 
Groups 3/4 2.39 1.14–5.00 
Groups 5/6 6.50 2.94–14.39 < 0.0001
MVD 0.1 
EORTC Low-risk group 1 
High-risk group 2.42 1.50–3.90 0.0003
MVD 1.04 1.01–1.06 0.006 
BJOC 01-1997 863-868  10/9/01  1:56 pm  Page 8661999) and these have been further correlated to prognosis in solid
tumours (O’Byrne et al, 1999). 
Accurate TNM staging is difficult to achieve in the majority of
patients with MM. Only a small proportion of patients are suitable
for radical surgery, which does allow accurate pathological TNM
staging, but even the validity of the International Mesothelioma
Interest Group TNM staging system has been questioned
(Sugarbaker et al, 1999). Therefore, biological markers may have
an important role in providing prognostic information, which is
not only of use in individual cases, but also crucial to the design
and interpretation of clinical trials. This study clearly demonstrates
that MVD is an independent prognostic factor in MM, which also
contributes significantly to the EORTC prognostic scoring system.
It is possible that the lack of contribution to the CALGB prog-
nostic groups is due to the inclusion of weight loss as a parameter
in this prognostic system. We found a near significant correlation
between high MVD and weight loss. Weight loss in cancer patients
is associated with raised inflammatory cytokine levels, including
interleukin (IL)-6 (Scott et al, 1996). IL-6 is an angiogenic growth
factor (Motro et al, 1990). Serum IL-6 levels correlate with the
platelet count in MM (Nakano et al, 1998). These observations are
in keeping with the finding of a positive correlation between
platelet count and both MVD and weight loss in our patient series. 
Other biological prognostic markers in MM include the cyto-
keratin marker Cyfra 21–1 (Schouwink et al, 1999), syndecan-1
(Kumar-Singh et al, 1998), bFGF (Kumar-Singh et al, 1999) and
Simian virus-40 sequences (Procopio et al, 2000). We have
recently presented data in operable non-small-cell lung cancer
indicating that MVD contributes to a biological prognostic model
which is independent of TNM stage (Cox et al, 2001). Using a
similar approach, it may be possible to create a biological staging
system in MM, which would avoid the current difficulties in
predicting outcome associated with TNM staging. In addition to
bFGF and IL-6, a number of other angiogenic factors have been
studied in MM, although correlation between their expression and
angiogenesis is poorly understood. These include HGF/SF (Tolnay
et al, 1998), IL-8 (Antony et al, 1996) and urokinase plasminogen
activator (Shetty et al, 1995). VEGF expression was correlated to
MVD in MM by Ohta (Ohta et al, 1999) but not in the Kumar-
Singh study (Kumar-Singh et al, 1999). However VEGF expres-
sion was not found to be a significant poor prognostic factor in
either study. 
Research into the mechanisms underlying angiogenesis has
resulted in the discovery of a number of potential anti-angiogenic
agents and endogenous angiostatic peptides, which are currently
undergoing investigation in solid tumours (Bicknell and Harris,
1996; Twardowski and Gradishar, 1997; Cherrington et al, 2000;
Eatock et al, 2000; O’Byrne et al, 2000; Talks and Harris, 2000).
These include: synthetic matrix metalloproteinase inhibitors (e.g.
Batimastat (Macaulay et al, 1999) and Marimastat (Steward,
1999)), cytokines and their modulators (e.g. interferon α -2a, IL-12
(Duda et al, 2000) and thalidomide (Calabrese and Fleischer,
2000)) and angiostatic factors (e.g. angiostatin (O’Reilly et al,
1994), endostatin (O’Reilly et al, 1997), TNP-470 (Gervaz and
Fontolliet, 1998) and platelet factor-4 (Gupta et al, 1995)). 
In conclusion, assessment of angiogenesis may have an impor-
tant role in the prognostic evaluation of MM and contribute to
currently established prognostic scoring systems. Investigation of
the mechanisms of angiogenesis in MM may provide further prog-
nostic information and help to rationalise therapy. Such markers
may be useful in the selection of patients for radical surgery and
chemotherapeutic treatment protocols including the use of anti-
angiogenic agents. 
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